Sessions

Principles of gene transfer and cell-based therapeutic strategies.
Mechanisms of action and clinical relevance of advanced therapies.
Translational foundations for gene and cell-based medicine.

AAV, lentiviral, adenoviral, and retroviral delivery platforms.
Vector engineering, safety, and tissue targeting strategies.
Clinical applications and regulatory considerations.

Lipid nanoparticles, polymers, and physical delivery methods.
Advantages and limitations of non-viral approaches.
Emerging innovations in gene delivery technologies.

CRISPR, base editing, and prime editing systems.
Precision genome modification and therapeutic design.
Ethical, safety, and translational challenges.

Engineering chimeric antigen receptor T cells.
Clinical successes in hematological malignancies.
Next-generation CAR designs and solid tumor challenges.

Natural killer cell engineering and innate immune therapies.
Off-the-shelf cell therapy strategies.
Clinical translation and scalability considerations.

Gene-modified stem cells for inherited disorders.
Ex vivo gene correction and long-term engraftment.
Safety and durability of therapeutic outcomes.

Therapies targeting monogenic and orphan diseases.
Clinical trial outcomes and approved gene therapies.
Access, affordability, and long-term follow-up.

Gene-based cancer treatment strategies.
Tumor microenvironment targeting and immune modulation.
Combination therapies and precision oncology.

Gene delivery to the central nervous system.
Treatment of neurodegenerative and neuromuscular disorders.
Clinical translation and safety evaluation.

Genetic modulation for heart and vascular diseases.
Angiogenic gene therapies and myocardial repair.
Clinical trial insights and future directions.

GMP-compliant manufacturing of advanced therapies.
Scale-up, automation, and quality assurance.
Cost and supply-chain challenges.

Design of early- and late-phase clinical trials.
Patient selection and clinical endpoints.
Regulatory approval pathways.

Immune responses to vectors and engineered cells.
Preclinical safety evaluation strategies.
Long-term patient monitoring.

Global regulatory pathways for gene and cell therapies.
Ethical considerations and patient consent.
Policy challenges in advanced therapeutics.

mRNA, siRNA, and antisense oligonucleotide therapies.
Delivery technologies and clinical applications.
Advances in RNA-based medicine.

Comparison of in vivo and ex vivo strategies.
Therapeutic design considerations.
Clinical decision-making frameworks.

AI-driven vector design and target discovery.
Digital monitoring of therapeutic outcomes.
Data-driven optimization of therapies.

Market access challenges for advanced therapies.
Reimbursement and health economics.
Scaling innovation from lab to market.

Next-generation gene editing and cell engineering.
Integration with AI and regenerative medicine.
Visionary approaches to curative healthcare.